Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.6% – Time to Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 4.6% during trading on Friday . The company traded as low as $9.80 and last traded at $9.87. Approximately 12,513,958 shares traded hands during trading, a decline of 51% from the average daily volume of 25,305,934 shares. The stock had previously closed at $10.35.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market capitalization of $3.64 billion, a PE ratio of -6.09 and a beta of 0.86. The company has a 50-day moving average price of $7.52 and a 200-day moving average price of $7.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc lifted its stake in shares of Recursion Pharmaceuticals by 0.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock valued at $2,774,000 after buying an additional 1,300 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the period. Axxcess Wealth Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 4.3% during the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after purchasing an additional 1,795 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock valued at $176,000 after purchasing an additional 1,875 shares during the period. Finally, Wedmont Private Capital increased its stake in Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock valued at $144,000 after purchasing an additional 2,000 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.